BMY Bristol Myers Squibb (BMY) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000014272
Congress · 1Form 144 · 2
Insider buyers, 180 days
0
Funds added, last quarter
1,187
13F, latest reported quarter
Conversions, 180 days
7
Codes C/M, not in net · $1.2M priced
What the filings say about BMY
Insiders, 180 days
-$437.2K net sold
2 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 2 sold
Latest: sale, 2026-05-07
Planned sales (Form 144), 90 days
$437.2K
2 notices
Bristol Myers Squibb insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, BRISTOL MYERS SQUIBB CO insiders sold a net $437.2K of stock across 50 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 33.3% of the 18,748 shares held after it.
- 1 other insider sold within 30 days.
- 1,187 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP,Chief Med Offr,Head of Dev Massacesi Cristian sold about $403.5K of BMY on Sep 9, 2026; 1 other insider sold within 30 days and 1,187 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Nov 4, 2024.
- The trade is 3.0% of the 16,862 shares held after it.
- 1 other insider sold within 30 days.
- 1,187 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP and Controller Holzer Phil M sold about $33.8K of BMY on Aug 25, 2026; 1 other insider sold within 30 days and 1,187 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Sep 2, 2025.
- The trade is 15.6% of the 163,729 shares held after it.
- No other insider sold within 30 days.
- 1,187 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Financial Officer Elkins David V sold about $1.6M of BMY on Apr 1, 2026; 1,187 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Sep 2, 2025.
- The trade is 2.8% of the 159,248 shares held after it.
- No other insider sold within 30 days.
- 1,187 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Financial Officer Elkins David V sold about $278.0K of BMY on Apr 1, 2026; 1,187 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Sep 13, 2022.
- The trade is 33.5% of the 167,379 shares held after it.
- No other insider sold within 30 days.
- 1,187 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Financial Officer Elkins David V sold about $2.7M of BMY on Sep 2, 2025, the largest insider sale at the company since 2023; 1,187 funds added in the latest 13F quarter.50 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$437.2K over 180 days
-$437.2K over 90 days
below 55% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
1,187 funds bought in last quarter
more than 99% of Pharma & Biotech
Revenue
-0.2% year over year
below 56% of Pharma & Biotech
Margin
14.6% net margin
more than 84% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
2.2% of the float short (float per yahoo 2026-10-26) · 3.0 days to cover · settled 2026-09-30
below 64% of Pharma & Biotech
The situation: each line is one rule over one dataset
2 clinical trials were terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch BMY
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+43.5%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns BMY: institutional holders (13F)
13F holdings, latest reported quarter
180,384,994 sh
$10.4B
133,337,856 sh
$7.7B
102,408,940 sh
$5.9B
71,713,465 sh
$4.2B
67,595,177 sh
$3.9B
Congress trades in BMY
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-05-07 · disclosed 35 days later
$15,001 - $50,000
Bought 2025-12-19 · disclosed 24 days later
$1,001 - $15,000
Sold 2025-12-18 · disclosed 28 days later
$1,001 - $15,000
Sold 2025-11-13 · disclosed 28 days later
$1,001 - $15,000
Bought 2025-11-12 · disclosed 33 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
BMY planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Massacesi Cristian
Filed 2026-09-09
$403.5K
Holzer Phil M
Filed 2026-08-25
$33.8K
BMY mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
First Trust Nasdaq Pharmaceuticals ETF
$2.3M position · as of 2026-06-30
6.3%
Independent Franchise Partners US Equity Fund
$79.7M position · as of 2026-06-30
5.9%
Integrity Dividend Summit Fund
$849.0K position · as of 2026-07-31
5.3%
Invesco S&P Ultra Dividend Revenue ETF
$50.2M position · as of 2026-05-31
4.7%
VanEck Pharmaceutical ETF
$39.3M position · as of 2026-06-30
4.5%
Cambiar Aggressive Value ETF
$3.0M position · as of 2026-07-31
4.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
525 registered trials, 188 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
125
Phase 1
25 active
67
Phase 2
15 active
102
Phase 3
49 active
17
Phase 4
7 active
1
Early Phase 1
0 active
147
Not applicable
65 active
66
Multi-phase
27 active
What changed recently
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in
2026-10-17 · Completion moved 2024-09-05 → 2024-10-10
Phase 3
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osi
2026-10-09 · Not Yet Recruiting → Recruiting
Phase 3
Asia Myelodysplastic Syndrome (MDS) Registry
2026-10-09 · Not Yet Recruiting → Recruiting
,
A Phase 1 Study of Navlimetostat Tablet Formulations
2026-10-08 · Completion moved 2026-08-31 → 2026-11-02
Phase 1
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelo
2026-10-07 · Completion moved 2014-05 → 2014-05-28
PHASE1,PHASE2
A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy Parti
2026-10-06 · Not Yet Recruiting → Recruiting
Phase 1
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Bristol-Myers Squibb Company Political Action Committee
Cycle 2026 · $598K spent
$632.0K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Dr. Chris Boerner
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$21.9M
$16.9M
$9.2M
+5%
+98%
2024
$18.8M
$21.2M
$7.7M
+5%
+54%
2022
$20.1M
$35.1M
$7.0M
+23%
+39%
2021
$19.8M
$16.5M
$7.1M
+3%
+26%
2020
$20.2M
$17.6M
$7.1M
+0%
+2%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $437.2K sold by insiders over 180 days, 1,187 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $437.2K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
BMY financials
Revenue growth
-0.2%
XBRL, annual
Net margin
14.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$49.2B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM BMY
| FY Dec 2025 | $48.2B |
| FY Dec 2024 | $48.3B |
| FY Dec 2023 | $45.0B |
| FY Dec 2022 | $46.2B |
| FY Dec 2021 | $46.4B |
| Jun 2026 | $13.0B |
| Mar 2026 | $11.5B |
| Dec 2025 | $12.5B |
| Sep 2025 | $12.2B |
| Jun 2025 | $12.3B |
| Mar 2025 | $11.2B |
| Dec 2024 | $12.3B |
| Sep 2024 | $11.9B |
At each fiscal year end
Single quarter
Net margin, TTM
+18.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM BMY
| FY Dec 2025 | +14.6% |
| FY Dec 2024 | -18.5% |
| FY Dec 2023 | +17.8% |
| FY Dec 2022 | +13.7% |
| FY Dec 2021 | +15.1% |
| Jun 2026 | +25.6% |
| Mar 2026 | +23.3% |
| Dec 2025 | +8.7% |
| Sep 2025 | +18.0% |
| Jun 2025 | +10.7% |
| Mar 2025 | +21.9% |
| Dec 2024 | +0.6% |
| Sep 2024 | +10.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$11.4B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM BMY
| FY Dec 2025 | $12.8B |
| FY Dec 2024 | $13.9B |
| FY Dec 2023 | $12.7B |
| FY Dec 2022 | $11.9B |
| FY Dec 2021 | $15.2B |
| Jun 2026 | $3.1B |
| Mar 2026 | $757.0M |
| Dec 2025 | $1.6B |
| Sep 2025 | $6.0B |
| Jun 2025 | $3.6B |
| Mar 2025 | $1.7B |
| Dec 2024 | $4.1B |
| Sep 2024 | $5.3B |
At each fiscal year end
Single quarter
Debt to equity
1.93x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity BMY
| FY Dec 2025 | 2.44x |
| FY Dec 2024 | 3.04x |
| FY Dec 2023 | 1.35x |
| FY Dec 2022 | 1.27x |
| FY Dec 2021 | 1.24x |
| Jun 2026 | 1.93x |
| Mar 2026 | 2.22x |
| Dec 2025 | 2.44x |
| Sep 2025 | 2.64x |
| Jun 2025 | 2.82x |
| Mar 2025 | 2.86x |
| Dec 2024 | 3.04x |
| Sep 2024 | 2.90x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.30x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt BMY
| FY Dec 2025 | 0.31x |
| FY Dec 2024 | 0.31x |
| FY Dec 2023 | 0.35x |
| FY Dec 2022 | 0.33x |
| FY Dec 2021 | 0.36x |
| Jun 2026 | 0.30x |
| Mar 2026 | 0.30x |
| Dec 2025 | 0.31x |
| Sep 2025 | 0.34x |
| Jun 2025 | 0.32x |
| Mar 2025 | 0.29x |
| Dec 2024 | 0.31x |
| Sep 2024 | 0.30x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+46.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity BMY
| FY Dec 2025 | +40.5% |
| FY Dec 2024 | -39.1% |
| FY Dec 2023 | +26.5% |
| FY Dec 2022 | +18.9% |
| FY Dec 2021 | +19.0% |
| Jun 2026 | +46.7% |
| Mar 2026 | +38.8% |
| Dec 2025 | +40.5% |
| Sep 2025 | +33.8% |
| Jun 2025 | +29.3% |
| Mar 2025 | +32.0% |
| Dec 2024 | -39.1% |
| Sep 2024 | -31.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+10.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets BMY
| FY Dec 2025 | +7.7% |
| FY Dec 2024 | -9.5% |
| FY Dec 2023 | +8.4% |
| FY Dec 2022 | +6.1% |
| FY Dec 2021 | +6.1% |
| Jun 2026 | +10.2% |
| Mar 2026 | +8.1% |
| Dec 2025 | +7.7% |
| Sep 2025 | +6.3% |
| Jun 2025 | +5.3% |
| Mar 2025 | +5.7% |
| Dec 2024 | -9.5% |
| Sep 2024 | -7.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital BMY
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed BMY
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
13.57x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing BMY
| FY Dec 2025 | 15.63x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 13.29x |
| FY Dec 2022 | 24.39x |
| FY Dec 2021 | 19.98x |
| Jun 2026 | 12.69x |
| Mar 2026 | 17.04x |
| Dec 2025 | 15.63x |
| Sep 2025 | 15.24x |
| Jun 2025 | 18.67x |
| Mar 2025 | 22.84x |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$160.2B
market value at close 2026-10-26 on 2026-07-22 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value BMY
| FY Dec 2025 | $144.7B |
| FY Dec 2024 | $154.0B |
| FY Dec 2023 | $132.7B |
| FY Dec 2022 | $183.2B |
| FY Dec 2021 | $169.0B |
| Jun 2026 | $152.1B |
| Mar 2026 | $158.4B |
| Dec 2025 | $144.7B |
| Sep 2025 | $125.1B |
| Jun 2025 | $130.8B |
| Mar 2025 | $162.6B |
| Dec 2024 | $154.0B |
| Sep 2024 | $146.8B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+9.1%
TTM free cash flow over market value at close 2026-10-26
FCF yield BMY
| FY Dec 2025 | +11.7% |
| FY Dec 2024 | +12.2% |
| FY Dec 2023 | +12.1% |
| FY Dec 2022 | +7.8% |
| FY Dec 2021 | +11.0% |
| Jun 2026 | +9.7% |
| Mar 2026 | +9.6% |
| Dec 2025 | +11.7% |
| Sep 2025 | +16.7% |
| Jun 2025 | +15.5% |
| Mar 2025 | +10.6% |
| Dec 2024 | +12.2% |
| Sep 2024 | +13.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.16x
P/E over trailing EPS growth of 83%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing BMY
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.43x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.15x |
| Mar 2026 | 0.51x |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $48.2B | $48.3B | $45.0B | $46.2B |
| Net income | $7.1B | -$8.9B | $8.0B | $6.3B |
| EPS (diluted) | 3.46 | -4.41 | 3.86 | 2.95 |
| Operating cash flow | $14.2B | $15.2B | $13.9B | $13.1B |
| Cash | $10.2B | $10.3B | $11.5B | $9.1B |
| Long-term debt | $42.9B | $47.6B | $36.7B | $35.1B |
| Buybacks | $0 | $0 | $5.2B | $8.0B |
| Dividends paid | $5.0B | $4.9B | $4.7B | $4.6B |
SEC XBRL, fiscal years, as known on 2026-10-27
BMY Stock Sonar score 6/7 axes
Find similar shapesCompareBMY ranks highest on profitability (91st percentile) and institutional and government (69th), and lowest on insider conviction (21st), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
BMY filings, in plain words
Are Bristol Myers Squibb insiders buying or selling BMY?
In the 180 days to 2026-10-27, Bristol Myers Squibb insiders were net sellers, a net $437.2K across purchases and sales reported on Form 4, by 2 sellers.
Have members of Congress traded BMY?
Yes. In the year to 2026-10-27, 1 House member disclosed buying BMY and 2 House members disclosed selling it; the latest on record is a sale by Mike Kelly dated 2026-05-07.
Are there planned insider sales of BMY?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $437.2K of stock; the latest, by Massacesi Cristian, was filed 2026-09-09.
Read the full summary
In the 180 days to 2026-10-27, Bristol Myers Squibb insiders were net sellers of BMY, a net $437.2K across purchases and sales reported on Form 4 by 2 sellers. In the year to 2026-10-27, 1 member of Congress disclosed buying BMY and 2 members disclosed selling it; the latest on record is a sale by Mike Kelly dated 2026-05-07. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $437.2K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
